Loading clinical trials...

Weight Management Aimed to Reduce Risk and Improve Outcomes From Radical Prostatectomy | Clinical Trials | Clareo Health

COMPLETEDNA

Weight Management Aimed to Reduce Risk and Improve Outcomes From Radical Prostatectomy

NCT03261271•University of Kansas Medical Center

View on ClinicalTrials.gov

Summary

The purpose of this study is to test how a weight management program affects substances in the blood called biomarkers that can show the presence or severity of cancer, compared to a standardized diet and exercise educational flyer.

Eligibility

Age

50 - No limit years

Sex

MALE

Healthy Volunteers

Inclusion Criteria

•Men newly diagnosed with PCa who are scheduled for radical prostatectomy (RP) (T1 or T2)
•Body Mass Index (BMI) 25-45 kg/m2
•Has internet access

Exclusion Criteria

•History of 5 alpha reductase inhibitors prior 3 months
•History of radiation therapy for cancer treatment
•Taking active cancer treatment
•Undergoing salvage therapy
•Castration-resistant PCa
•Evidence of metastasis
•Evidence of biochemical recurrence
•High risk medical condition (e.g. kidney disease, uncontrolled diabetes, etc.)

Locations (1)

University of Kansas Medical Center

Kansas City, Kansas, United States

Key Dates

Start Date

November 2, 2017

Primary Completion Date

November 28, 2023

Completion Date

March 25, 2025

Last Updated

April 13, 2025

Enrollment

ACTUAL participants

Conditions

ObesityProstate Cancer

Interventions

Weight Loss Program

BEHAVIORAL

Standardized educational flyer

BEHAVIORAL

Weight Maintenance Program

BEHAVIORAL

Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women

NCT07472881

MenopausePerimenopause+2 more

View study

RECRUITING

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

NCT01143454

Metabolic DiseaseObesity+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 13, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Weight Management Aimed to Reduce Risk and Improve Outcomes From Radical Prostatectomy

Inclusion Criteria

Exclusion Criteria

Multi-Acupoint Laser Therapy for Body Shape and Composition in Obese Menopausal Women

Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate Cancer